On March 24, 2020 Norgine B.V. ("Norgine") reported the acquisition of Azanta A/S, a specialty biopharmaceutical company operating within women’s healthcare, addiction medicine and oncology (Press release, azanta, MAR 24, 2020, View Source [SID1234555807]). Azanta becomes a wholly-owned subsidiary of Norgine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As a result of the transaction, Norgine acquires Azanta’s portfolio of products, including Angusta for labour induction and Nimorazole, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. Angusta was approved in Q1 2017 in the Nordics, and in Q4 2017 in France and 10 CEE countries. Regulatory approval for the rest of Europe is expected to be filed in H1 2020. Nimorazole has EMA orphan drug status and is ready for Phase III stage development.
Azanta A/S is headquartered in Denmark with pharmaceutical sales subsidiaries in the other Nordic countries and in France. Norgine has a direct presence in 12 European countries, as well as Australia and New Zealand and has a strong track-record of successfully bringing products to market across Europe. Norgine also has a strong global network of partnerships in non-Norgine markets. Norgine’s European experience, fully integrated infrastructure and exceptional partnership approach enables it to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access.
This acquisition further strengthens Norgine’s position as a leading European specialist pharmaceutical company.
Peter Stein, CEO of Norgine, says: "Our commitment to transforming people’s lives drives everything we do and we are very proud to welcome the Azanta team and their portfolio of specialty products to Norgine. This transaction will enable us to strengthen our business in Europe and ultimately to help more patients."